Comparison of the efficacy and safety of etodolac and piroxicam in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 24, Issue SUPPL. 47, 1997, Pages 10-16

  Lightfoot, Robert ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Etodolac Study 326 Rheumatoid Arthritis Investigators Group   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antiinflammatory agents; Etodolac; Nonsteroidal; Piroxicam; Rheumatoid arthritis

Indexed keywords

ETODOLAC; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ANTIMALARIAL AGENT; ANUSOL; CIMETIDINE; CORTICOSTEROID; GOLD SALT; METHOTREXATE; MISOPROSTOL; PENICILLAMINE; PREDNISONE; RANITIDINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EVALUATION; FEMALE; HEMATOCRIT; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; ABDOMINAL PAIN; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HEADACHE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ETODOLAC; EVALUATION STUDIES; FEMALE; HEMATOCRIT; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PIROXICAM;

EID: 0031050476     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Briançon D, Peterschmitt J, Laviec G: Double-blind parallel-group evaluation of the safety and efficacy of etodolac capsules compared with piroxicam capsules in patients with rheumatoid arthritis. Acta Ther 1991;12:35-47.
2. Schattenkirchner M: Double-blind comparison of etodolac and piroxicam in patients with rheumatoid arthritis. Curr Med Res Opin 1991;12:497-506.
3. Ropes MW, Bennet FA, Cobb S: 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 1959;2:16-20.
4. Dunagan FM, McGill PE, Kelman AW, Whiting B: Naproxen dose and concentration: Response relationship in rheumatoid arthritis. Br J Rheumatol 1988;27:48-53.
5. Zvaifler N: A review of the antiarthritic efficacy and safety of etodolac. Clin Rheumatol 1989;(suppl 1)8:43-53.
6. Karbowski A: A global safety evaluation of etodolac. Clin Rheumatol 1989;(suppl 1)8:73-9.
7. ®) in France: An assessment of safety. Rheumatol Int 1990;10:29-34.
8. Serni U: Global safety of etodolac: Reports from worldwide post-marketing surveillance studies. Rheumatol Int 1990;10:23-7.
9. Taha AS, McLaughlin S, Sturrick RD, Russell RI: Evaluation of the efficacy and comparative effects on gastric and duodenal mucosa of etodolac and naproxen in patients with rheumatoid arthritis using endoscopy. Br J Rheumatol 1989;28:329-32.
10. Arnold JD, Mullane JF, Hayden DM, et al: Etodolac, aspirin, and gastrointestinal microbleeding. Clin Pharmacol Ther 1984;35:716-21.
11. Arnold JD, Salom IL, Berger AE, et al: Comparison of gastrointestinal microbleeding associated with use of etodolac, ibuprofen, indomethacin, and naproxen in normal subjects. Curr Ther Res 1985;37:730-8.
12. Lanza F, Panagides J, Salom IL: Etodolac compared with aspirin: An endoscopic study of the gastrointestinal tracts of normal volunteers. J Rheumatol 1986;13:299-303.
13. Lanza F, Rack MF, Lynn M, Wolf J, Sanda M: An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987;14:338-41.